The Eradication of Carcinogenic Viruses in Established Solid Cancers

References

• Vandeven N, Nghiem P. Pathogen-driven cancers and emerging immune therapeutic strategies. Cancer Immunol Res. 2014;2(1):9–14. doi:10.1158/2326-6066.CIR-13-0179
   PubMed Web of Science ®Google Scholar
• IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.
   Google Scholar
• Ablashi DV, Chatlynne LG, Whitman JE, Cesarman E. Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev. 2002;15(3):439–464. doi:10.1128/CMR.15.3.439-464.2002
   PubMed Web of Science ®Google Scholar
• Kuwamoto S, Higaki H, Kanai K, et al. Association of Merkel cell polyomavirus infection with morphologic differences in Merkel cell carcinoma. Hum Pathol. 2011;42(5):632–640. doi:10.1016/j.humpath.2010.09.011
   PubMed Web of Science ®Google Scholar
• Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010;10(12):878–889. doi:10.1038/nrc2961
   PubMed Web of Science ®Google Scholar
• Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine. 2008;43(3):336–341. doi:10.1016/j.cyto.2008.07.009
   PubMed Web of Science ®Google Scholar
• Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011;17(9):2619–2627. doi:10.1158/1078-0432.CCR-10-1114
   PubMed Web of Science ®Google Scholar
• Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 2018;9:847. doi:10.3389/fimmu.2018.00847
   PubMed Web of Science ®Google Scholar
• Soliman SHA, Orlacchio A, Verginelli F. Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis. Microorganisms. 2021;9(6):1179. doi:10.3390/microorganisms9061179
   PubMed Web of Science ®Google Scholar
• Song S, Gong S, Singh P, Lyu J, Bai Y. The interaction between mitochondria and oncoviruses. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):481–487. doi:10.1016/j.bbadis.2017.09.023
   PubMed Web of Science ®Google Scholar
• Kori M, Arga KY. Pathways involved in viral oncogenesis: new perspectives from virus-host protein interactomics. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165885. doi:10.1016/j.bbadis.2020.165885
   PubMed Web of Science ®Google Scholar
• Çuburu N, Graham BS, Buck CB, et al. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest. 2012;122(12):4606–4620. doi:10.1172/JCI63287
   PubMed Web of Science ®Google Scholar
• Abbott RJ, Quinn LL, Leese AM, Scholes HM, Pachnio A, Rickinson AB. CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response. J Immunol. 2013;191(11):5398–5409. doi:10.4049/jimmunol.1301629
   PubMed Web of Science ®Google Scholar
• Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215–4225. doi:10.1128/JVI.02844-06
   PubMed Web of Science ®Google Scholar
• Wieland D, Kemming J, Schuch A, et al. TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation. Nat Commun. 2017;8:15050. doi:10.1038/ncomms15050
   PubMed Web of Science ®Google Scholar
• Lambert M, Gannagé M, Karras A, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood. 2006;108(12):3871–3880. doi:10.1182/blood-2006-03-014225
   PubMed Web of Science ®Google Scholar
• Wölfl M, Kuball J, Eyrich M, Schlegel PG, Greenberg PD. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A. 2008;73(11):1043–1049. doi:10.1002/cyto.a.20594
   PubMedGoogle Scholar
• Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23(2):375–382. doi:10.1038/leu.2008.272
   PubMed Web of Science ®Google Scholar
• Chatterjee B, Deng Y, Holler A, et al. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo. PLoS Pathog. 2019;15(5):e1007748. doi:10.1371/journal.ppat.1007748
   PubMed Web of Science ®Google Scholar
• Clements DM, Crumley B, Chew GM, et al. Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection. Front Immunol. 2021;12:608890. doi:10.3389/fimmu.2021.608890
   PubMed Web of Science ®Google Scholar
• Ma SD, Xu X, Jones R, et al. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathog. 2016;12(5):e1005642. doi:10.1371/journal.ppat.1005642
   PubMed Web of Science ®Google Scholar
• Blair T, Baird J, Bambina S, et al. ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control. Sci Rep. 2022;12(1):14954. doi:10.1038/s41598-022-19256-8
   PubMed Web of Science ®Google Scholar
• Derré L, Rivals JP, Jandus C, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest. 2010;120(1):157–167. doi:10.1172/JCI40070
   PubMed Web of Science ®Google Scholar
• Ganusov VV, Lukacher AE, Byers AM. Persistence of viral infection despite similar killing efficacy of antiviral CD8(+) T cells during acute and chronic phases of infection. Virology. 2010;405(1):193–200. doi:10.1016/j.virol.2010.05.029
   PubMed Web of Science ®Google Scholar
• Hibma MH. The immune response to papillomavirus during infection persistence and regression. Open Virol J. 2012;6:241–248. doi:10.2174/1874357901206010241
   PubMedGoogle Scholar
• Cheng D, Qiu K, Rao Y, et al. Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma. Elife. 2023;12:e82705. doi:10.7554/eLife.82705
   PubMed Web of Science ®Google Scholar
• Krishna S, Ulrich P, Wilson E, et al. Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. Cancer Res. 2018;78(21):6159–6170. doi:10.1158/0008-5472.CAN-18-0163
   PubMed Web of Science ®Google Scholar
• Park JJ, Wong DK, Wahed AS, et al. Hepatitis B Research Network. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology. 2016;150(3):684–695.e5. doi:10.1053/j.gastro.2015.11.050
   PubMed Web of Science ®Google Scholar
• Yang F, Yu X, Zhou C, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 2019;15(4):e1007690. doi:10.1371/journal.ppat.1007690
   PubMed Web of Science ®Google Scholar
• Hoogeveen RC, Robidoux MP, Schwarz T, et al. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut. 2019;68(5):893–904. doi:10.1136/gutjnl-2018-316644
   PubMed Web of Science ®Google Scholar
• Baudi I, Kawashima K, Isogawa M. HBV-Specific CD8+ T-Cell Tolerance in the Liver. Front Immunol. 2021;12:721975. doi:10.3389/fimmu.2021.721975
   PubMed Web of Science ®Google Scholar
• Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med. 2021;10(5):991. doi:10.3390/jcm10050991
   PubMed Web of Science ®Google Scholar
• Barili V, Fisicaro P, Montanini B, et al. Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. Nat Commun. 2020;11(1):604. doi:10.1038/s41467-019-14137-7
   PubMed Web of Science ®Google Scholar
• Hensel N, Gu Z, Sagar W, et al. Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection. Nat Immunol. 2021;22(2):229–239. doi:10.1038/s41590-020-00817-w
   PubMed Web of Science ®Google Scholar
• Lepone L, Rappocciolo G, Knowlton E, et al. Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins. Clin Vaccine Immunol. 2010;17(10):1507–1516. doi:10.1128/CVI.00189-10
   PubMedGoogle Scholar
• Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major histocompatibility complex class I molecules by Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000;74(11):5300–5309. doi:10.1128/jvi.74.11.5300-5309.2000
   PubMed Web of Science ®Google Scholar
• Coscoy L, Ganem D. Kaposi’s sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci U S A. 2000;97(14):8051–8056. doi:10.1073/pnas.140129797
   PubMed Web of Science ®Google Scholar
• Guihot A, Dupin N, Marcelin AG, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis. 2006;194(8):1078–1088. doi:10.1086/507648
   PubMed Web of Science ®Google Scholar
• Lidenge SJ, Tso FY, Ngalamika O, et al. Lack of CD8+ T-cell co-localization with Kaposi’s sarcoma-associated herpesvirus infected cells in Kaposi’s sarcoma tumors. Oncotarget. 2020;11(17):1556–1572. doi:10.18632/oncotarget.27569
   PubMedGoogle Scholar
• Espíndola OM, Siteur-van Rijnstra E, Frankin E, et al. Early Effects of HTLV-1 Infection on the Activation, Exhaustion, and Differentiation of T-Cells in Humanized NSG Mice. Cells. 2021;10(10):2514. doi:10.3390/cells10102514
   PubMed Web of Science ®Google Scholar
• Hanon E, Stinchcombe JC, Saito M, et al. Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity. 2000;13(5):657–664. doi:10.1016/s1074-7613(00)00065-0
   PubMed Web of Science ®Google Scholar
• Maini MK, Gudgeon N, Wedderburn LR, Rickinson AB, Beverley PC. Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J Immunol. 2000;165(10):5729–5737. doi:10.4049/jimmunol.165.10.5729
   PubMed Web of Science ®Google Scholar
• Callan MF, Tan L, Annels N, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med. 1998;187(9):1395–1402. doi:10.1084/jem.187.9.1395
   PubMed Web of Science ®Google Scholar
• Imperiale MJ, Jiang M. Polyomavirus Persistence. Annu Rev Virol. 2016;3(1):517–532. doi:10.1146/annurev-virology-110615-042226
   PubMedGoogle Scholar
• Wilson JJ, Pack CD, Lin E, et al. CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. J Immunol. 2012;188(9):4340–4348. doi:10.4049/jimmunol.1103727
   PubMed Web of Science ®Google Scholar
• Vezys V, Masopust D, Kemball CC, et al. Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med. 2006;203(10):2263–2269. doi:10.1084/jem.20060995
   PubMed Web of Science ®Google Scholar
• Lei J, Arroyo-Mühr LS, Lagheden C, et al. Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. J Clin Oncol. 2022;40(14):1522–1528. doi:10.1200/JCO.21.01930
   PubMed Web of Science ®Google Scholar
• Zhou P, Yu YF, Lian CL, Wang J, Zhuo RG, Wu SG. Survival Outcomes and Treatment Decision by Human Papillomavirus Status Among Patients With Stage IVC Head and Neck Squamous Cell Carcinoma. Front Oncol. 2021;11:668066. doi:10.3389/fonc.2021.668066
   PubMedGoogle Scholar
• Xue X, Liao W, Xing Y. Comparison of clinical features and outcomes between HBV- related and non-B non-C hepatocellular carcinoma. Infect Agent Cancer. 2020;15:11. doi:10.1186/s13027-020-0273-2
   PubMed Web of Science ®Google Scholar
• Omichi K, Shindoh J, Yamamoto S, et al. Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: a Subgroup Analysis of Patients with a History of Hepatitis B Infection. Ann Surg Oncol. 2015;22 Suppl 3:S1034. doi:10.1245/s10434-015-4845-0
   PubMed Web of Science ®Google Scholar
• Wang X, Liu X, Wang P, et al. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia. J Hepatocell Carcinoma. 2021;8:1253–1267. doi:10.2147/JHC.S330301
   PubMed Web of Science ®Google Scholar
• Yeh ML, Liang PC, Tsai PC, et al. Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. Cancers (Basel). 2021;13(14):3455. doi:10.3390/cancers13143455
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res. 2020;12:5323–5330. doi:10.2147/CMAR.S254580
   PubMed Web of Science ®Google Scholar
• Tagkou NM, Goossens N, Negro F. Impact of direct-acting antivirals on the recurrence of hepatocellular carcinoma in chronic hepatitis C. Hepatoma Res. 2022;8:28. doi:10.20517/2394-5079.2022.08
   Google Scholar
• Muzica CM, Stanciu C, Huiban L, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: a debate near the end. World J Gastroenterol. 2020;26(43):6770–6781. doi:10.3748/wjg.v26.i43.6770
   PubMed Web of Science ®Google Scholar
• Esser S, Schöfer H, Hoffmann C, et al. S1 Guidelines for the Kaposi Sarcoma. J Dtsch Dermatol Ges. 2022;20(6):892–904. doi:10.1111/ddg.14788
   Web of Science ®Google Scholar
• El Hajj H, Tsukasaki K, Cheminant M, Bazarbachi A, Watanabe T, Hermine O. Novel Treatments of Adult T Cell Leukemia Lymphoma. Front Microbiol. 2020;11:1062. doi:10.3389/fmicb.2020.01062
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177–4183. doi:10.1200/JCO.2010.28.0669
   PubMed Web of Science ®Google Scholar
• Nohtani M, Vrzalikova K, Ibrahim M, et al. Impact of Tumour Epstein--Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): a Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL. Cancers (Basel). 2022;14(17):4297. doi:10.3390/cancers14174297
   PubMed Web of Science ®Google Scholar
• Claviez A, Tiemann M, Lüders H, et al. Impact of latent Epstein--Barr virus infection on outcome in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol. 2005;23(18):4048–4056. doi:10.1200/JCO.2005.01.701
   PubMed Web of Science ®Google Scholar
• Alami IE, Gihbid A, Charoute H, et al. Prognostic value of Epstein--Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis. Pan Afr Med J. 2022;41:6. doi:10.11604/pamj.2022.41.6.28946
   PubMed Web of Science ®Google Scholar
• Yang A, Wijaya WA, Lie Y, et al. The impact of Merkel Cell polyomavirus positivity on prognosis of Merkel cell carcinoma: a systematic review and meta-analysis. Front Oncol. 2022. doi:10.3389/fonc.2022.1020805
   Web of Science ®Google Scholar
• Hatta MNA, Mohamad Hanif EA, Chin SF, Neoh HM. Pathogens and Carcinogenesis: a Review. Biology (Basel). 2021;10(6):533. doi:10.3390/biology10060533
   PubMedGoogle Scholar
• Baral S, Antia R, Dixit NM. A dynamical motif comprising the interactions between antigens and CD8 T cells may underlie the outcomes of viral infections. Proc Natl Acad Sci U S A. 2019;116(35):17393–17398. doi:10.1073/pnas.1902178116
   PubMed Web of Science ®Google Scholar
• Tian L, Zhou W, Wu X, et al. CTLs: killers of intracellular bacteria. Front Cell Infect Microbiol. 2022;12:967679. doi:10.3389/fcimb.2022.967679
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Varga SM. The CD8 T Cell Response to Respiratory Virus Infections. Front Immunol. 2018;9:678. doi:10.3389/fimmu.2018.00678
   PubMed Web of Science ®Google Scholar
• Elkoshi Z. The Binary Model of Chronic Diseases Applied to COVID-19. Front Immunol. 2021;12:716084. doi:10.3389/fimmu.2021.716084
   PubMed Web of Science ®Google Scholar
• Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346–1358. doi:10.1038/s41590-020-0769-3
   PubMed Web of Science ®Google Scholar
• Yang -Z-Z, Grote DM, Ziesmer SC, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Investig. 2012;122:1271–1282. doi:10.1172/JCI59806
   PubMed Web of Science ®Google Scholar
• Josefsson SE, Huse K, Kolstad A, et al. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. Clin Cancer Res. 2018;24(4):870.
   PubMed Web of Science ®Google Scholar
• Yang -Z-Z, Kim HJ, Villasboas JC, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8:61425–61439. doi:10.18632/oncotarget.18251
   PubMedGoogle Scholar
• Elkoshi Z. The Binary Classification Of Chronic Diseases. J Inflamm Res. 2019;12:319–333. doi:10.2147/JIR.S227279
   PubMed Web of Science ®Google Scholar
• Cárdenas D, Vélez G, Orfao A, et al. Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired. Clin Exp Immunol. 2015;182(2):173–183. doi:10.1111/cei.12682
   PubMed Web of Science ®Google Scholar
• Miao BP, Zhang RS, Li M, et al. Nasopharyngeal cancer-derived microRNA-21 promotes immune suppressive B cells. Cell Mol Immunol. 2015;12(6):750–756. doi:10.1038/cmi.2014.129
   PubMed Web of Science ®Google Scholar
• Zheng X, Huang Y, Li K, Luo R, Cai M, Yun J. Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies. Viruses. 2022;14(5):1017. doi:10.3390/v14051017
   PubMed Web of Science ®Google Scholar
• Rentsch CA, Birkhäuser FD, Biot C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014;66(4):677–688. doi:10.1016/j.eururo.2014.02.061
   PubMed Web of Science ®Google Scholar
• Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007;61(6):299–305. doi:10.1016/j.biopha.2007.05.004
   PubMed Web of Science ®Google Scholar
• Kumar NP, Padmapriyadarsini C, Rajamanickam A, et al. BCG vaccination induces enhanced frequencies of memory T cells and altered plasma levels of common γc cytokines in elderly individuals. PLoS One. 2021;16(11):e0258743. doi:10.1371/journal.pone.0258743
   PubMed Web of Science ®Google Scholar
• Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: an Adaptable Pathogen Associated With Multiple Human Diseases. Front Cell Infect Microbiol. 2018;8:158. doi:10.3389/fcimb.2018.00158
   PubMed Web of Science ®Google Scholar
• Cross ML, Aldwell FE, Griffin JF, Mackintosh CG. Intracellular survival of virulent Mycobacterium bovis and M. bovis BCG in ferret macrophages. Vet Microbiol. 1999;66(3):235–243. doi:10.1016/s0378-1135(99)00011-5
   PubMed Web of Science ®Google Scholar
• Nolz JC. Molecular mechanisms of CD8(+) T cell trafficking and localization. Cell Mol Life Sci. 2015;72(13):2461–2473. doi:10.1007/s00018-015-1835-0
   PubMed Web of Science ®Google Scholar
• Immunity to Infection. Primer to the Immune Response. 2014:295–332. doi:10.1016/B978-0-12-385245-8.00013-3
   Google Scholar
• Oh JD, Karam SM, Gordon JI. Intracellular Helicobacter pylori in gastric epithelial progenitors. Proc Natl Acad Sci U S A. 2005;102(14):5186–5191. doi:10.1073/pnas.0407657102
   PubMed Web of Science ®Google Scholar
• Deng R, Zheng H, Cai H, Li M, Shi Y, Ding S. Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. Front Immunol. 2022;13:923477. doi:10.3389/fimmu.2022.923477
   PubMedGoogle Scholar
• Xue LJ, Mao XB, Liu XB, et al. Activation of CD3+ T cells by Helicobacter pylori DNA vaccines in potential immunotherapy of gastric carcinoma. Cancer Biol Ther. 2019;20(6):866–876. doi:10.1080/15384047.2019.1579957
   PubMed Web of Science ®Google Scholar
• Ramachandran M, Jin C, Yu D, Eriksson F, Essand M. Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration. J Immunol. 2014;193(5):2287–2296. doi:10.4049/jimmunol.1400339
   PubMed Web of Science ®Google Scholar
• Tan MP, Pedersen J, Zhan Y, et al. CD8+ T cells are associated with severe gastritis in Helicobacter pylori-infected mice in the absence of CD4+ T cells. Infect Immun. 2008;76(3):1289–1297. doi:10.1128/IAI.00779-07
   PubMed Web of Science ®Google Scholar
• Koch MRA, Gong R, Friedrich V, et al. CagA-specific Gastric CD8+ Tissue-Resident T Cells Control Helicobacter pylori During the Early Infection Phase. Gastroenterology. 2023;164(4):550–566. doi:10.1053/j.gastro.2022.12.016
   PubMed Web of Science ®Google Scholar
• Shirai M, Arichi T, Nakazawa T, Berzofsky JA. Persistent infection by Helicobacter pylori down-modulates virus-specific CD8+ cytotoxic T cell response and prolongs viral infection. J Infect Dis. 1998;177(1):72–80. doi:10.1086/513827
   PubMed Web of Science ®Google Scholar
• Jia Z, Zheng M, Jiang J, et al. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis. BMC Cancer. 2022;22(1):155. doi:10.1186/s12885-022-09222-y
   PubMed Web of Science ®Google Scholar
• Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al.; EGILS group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747–758. doi:10.1136/gut.2010.224949
   PubMed Web of Science ®Google Scholar
• Xie Q, Ding J, Chen Y. Role of CD8+ T lymphocyte cells: interplay with stromal cells in tumor microenvironment. Acta Pharm Sin B. 2021;11(6):1365–1378. doi:10.1016/j.apsb.2021.03.027
   PubMed Web of Science ®Google Scholar
• Wang J, Ke XY. The four types of Tregs in malignant lymphomas. J Hematol Oncol. 2011;4:50. doi:10.1186/1756-8722-4-50
   PubMed Web of Science ®Google Scholar
• Bai Y, He T, Zhang L, et al. Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-et al. lymphoma: a systematic review and meta-analysis. BMJ Open. 2022;12(9):e060659. doi:10.1136/bmjopen-2021-060659
   PubMed Web of Science ®Google Scholar
• Elkoshi Z. “High Treg” Inflammations Promote (Most) Non-Hematologic Cancers While “Low Treg” Inflammations Promote Lymphoid Cancers. J Inflamm Res. 2020;13:209–221. doi:10.2147/JIR.S249384
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108(9):2957–2964. doi:10.1182/blood-2006-04-018218
   PubMed Web of Science ®Google Scholar
• D’Arena G, Vitale C, Coscia M, et al. Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. J Immunol Res. 2017;2017:1832968. doi:10.1155/2017/1832968
   PubMed Web of Science ®Google Scholar
• Menéndez V, Solórzano JL, Fernández S, Montalbán C, García JF. The Hodgkin Lymphoma Immune Microenvironment: turning Bad News into Good. Cancers (Basel). 2022;14(5):1360. doi:10.3390/cancers14051360
   PubMed Web of Science ®Google Scholar
• Elkoshi Z. On the Prognostic Power of Tumor-Infiltrating Lymphocytes - A Critical Commentary. Front Immunol. 2022;13:892543. doi:10.3389/fimmu.2022.892543
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin’s lymphoma. Cancer Res. 2006;66(20):10145–10152. doi:10.1158/0008-5472.CAN-06-1822
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS One. 2013;8(3):e59456. doi:10.1371/journal.pone.0059456
   PubMed Web of Science ®Google Scholar
• Greenbaum AM, Fromm JR, Gopal AK, Houghton AM. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8+ T-cells despite immune checkpoint signaling. Blood Res. 2022;57(2):117–128. doi:10.5045/br.2022.2021145
   PubMed Web of Science ®Google Scholar
• Autio M, Leivonen SK, Brück O, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2021;106(3):718–729. doi:10.3324/haematol.2019.243626
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Miyoshi H, Ohshima K. Tumor microenvironment of adult T-cell leukemia/lymphoma. J Clin Exp Hematop. 2021;61(4):202–209. doi:10.3960/jslrt.21007
   PubMed Web of Science ®Google Scholar